Pfizer COVID-19 jab safe and effective in kids aged 6 months to 4 years

Embargoed until: Publicly released: 2023-02-16 09:00

International

Pfizer-BioNTech_COVID-19_vaccine_(2020)_C By U.S. Secretary of Defense, CC BY 2.0

A 'gold standard' placebo-controlled medical trial of the Pfizer BioNTech COVID-19 mRNA vaccine found three doses are safe and effective for kids aged between six months and four years. The vaccine was tested on 1,776 children aged between six months and two years, and 2,750 children aged between two and four years. Immune responses were measured one month after the third dose, and the vaccine was found to be 73.2% effective against symptomatic COVID-19 from a week after dose three. Adverse reactions were mostly mild to moderate, the scientists say, and no kids suffered the most severe category of reactions. The study was funded by Pfizer and BioNTech.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page The URL will go live after the embargo ends

Journal/
conference: New England Journal of Medicine

Research:Paper

Organisation/s: Pfizer, BioNTech, Baylor College of Medicine, USA

Funder: Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.

Media Contact/s

Contact details are only visible to registered journalists.